| Liu, Peng |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT05316246: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 40 | NA | Brentuximab Vedotin in Combination with Tislelizumab | Shanghai Zhongshan Hospital, Takeda, BeiGene | NK/T Cell Lymphoma Nos | 06/24 | 12/24 | | |
NCT05436223: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Human CD19Targeted T Cells Injection, CD19 CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Zhongshan Hospital | B-cell Non-Hodgkin's Lymphoma | 08/24 | 08/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT05940051: Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 35 | RoW | Zanubrutinib, Polatuzumab vedotin and Rituximab | Peng Liu | Diffuse Large B Cell Lymphoma | 07/25 | 12/25 | | |
| Recruiting | 2 | 30 | RoW | Zanubrutinib, Polatuzumab Vedotin, Rituximab, ZPR | Peng Liu | Diffuse Large B Cell Lymphoma | 07/25 | 12/25 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT03720457: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. |
|
|
| Recruiting | 1 | 18 | RoW | Human CD19 targeted T Cells Injection | Hrain Biotechnology Co., Ltd., Shanghai Zhongshan Hospital | CD19-positive, Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 10/21 | 10/23 | | |
| Recruiting | 1 | 57 | RoW | TQB3473 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Hematological Malignancies | 12/21 | 06/22 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Recruiting | 1 | 140 | RoW | TQB2934 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Multiple Myeloma | 10/24 | 10/25 | | |
NCT06700395: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma |
|
|
| Recruiting | 1 | 136 | RoW | TQB2029 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Multiple Myeloma | 03/26 | 03/28 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
NCT06760052: Longitudinal Data Registry of Plasma Cell Dyscrasia |
|
|
| Recruiting | N/A | 2000 | RoW | | Shanghai Zhongshan Hospital | Multiple Myeloma and Other Plasma Cell Neoplasms | 12/27 | 12/28 | | |
NCT06203652: The Pathogenesis and Prognostic Factors of Lymphoma |
|
|
| Recruiting | N/A | 2000 | RoW | Real-world regimen | Shanghai Zhongshan Hospital | Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma | 12/27 | 12/28 | | |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
CHAPERONE, NCT05965115: The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The Study |
|
|
| Recruiting | N/A | 10000 | RoW | Sample of Blood | Shanghai Zhongshan Hospital | Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | 08/25 | 08/35 | | |
NCT05623904: Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis |
|
|
| Recruiting | N/A | 1056 | RoW | Carotid Revascularization, Medical Treatment | Xuanwu Hospital, Beijing, China-Japan Friendship Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Zhengzhou University, Changhai Hospital, Peking Union Medical College Hospital, Hebei General Hospital, The Second Hospital of Hebei Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, People's Hospital of Xinjiang Uygur Autonomous Region, Fifth Affiliated Hospital of Zhengzhou University | Carotid Artery Stenting, Carotid Endarterectomy, Best Medical Treatment, Carotid Artery Stenosis Asymptomatic | 12/25 | 12/25 | | |
| Gao, Xueliang |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
